reports
- GlobalData Healthcare Department
Concordia International Corp (CXR) - Financial Analysis Review
Concordia International Corp (CXR) - Financial Analysis Review Summary Concordia International Corp (Concordia), formerly Concordia Healthcare Corp is a healthcare products provider that offers orphan drugs. The company undertakes the management and acquisition of legacy pharmaceutical products, orphan drugs and medical devices for diabetics. Its products comprise Orapred, Donnatal, Ulesfia, Zonegran, Dibenzyline, Dutoprol, Dyrenium, Fortaz, Kayexalate, Lanoxin, Parnate, Nilandron, and Uroxatr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.